The hunt for a better cure for inflammation

In 2020, Gesynta raised SEK 190 million in one of the year’s largest private biotech investments in the Nordic region. Now the company is one step closer to a new drug for systemic sclerosis. The future promises several innovative treatments for a number of inflammatory diseases, including cardiovascular disease and cancer.